Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

148 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators will be determining whether a once weekly injectable medication Bydureon versus placebo is able to reduce the development of atherosclerosis.

Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies will provide novel information about the temporal relationship between Bydureon induced changes in risk factors, endothelial function and atherosclerosis progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stop Atherosclerosis in Native Diabetics Study

NCT00147251

Cardiovascular Disease Hypertension Hyperlipidemia +2 more

COMPLETED PHASE4

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859

Type II Diabetes Atherosclerosis

RECRUITING PHASE4

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985

Healthy Volunteers

COMPLETED PHASE1

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

NCT02915198

Prediabetic State Atherosclerosis Metformin

RECRUITING PHASE4

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

NCT03829046

Atherosclerotic Vascular Disease Type2 Diabetes Microvascular Dysfunction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

148 typical T2DM patients (ages 21-75) will participate in a rolling recruitment over approximately 2.25 years and be randomly allocated for 18 months to Bydureon (2 mg/week) or matching placebo subcutaneous injections 1x/week in a 2:1 ratio. Participants are expected to have a wide range of cardiovascular (CVD) risk and will therefore allow us to explore the importance of disease extent at baseline as a predictor of response. Blocked randomization will be used to ensure equal distribution of gender and CVD history. Carotid plaque MRI assessments will be performed at baseline, 9 and 18 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bydureon

injectable medication Bydureon

Group Type EXPERIMENTAL

Bydureon

Intervention Type DRUG

once weekly injection

Placebo

a similar looking injectable

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

once weekly injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bydureon

once weekly injection

Intervention Type DRUG

placebo

once weekly injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

long-acting exenatide inactive agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only
* take stable doses of oral antihyperglycemic agents with or without long-acting insulin
* must have a regular primary care provider (PCP) that is amenable to patient study participation and will facilitate (blinded to the treatment) the research team's study protocol efforts

Exclusion Criteria

* type 1 diabetes mellitus (T1DM)
* current or recent glucagon-like peptide 1 receptor (GLP-1R) agonist use
* contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam)
* screening carotid ultrasound plaque thickness of \<0.75 mm, prior or anticipated carotid stenting or endarterectomy
* recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma
* patients with Multiple Endocrine Neoplasia syndrome type 2
* serious hypersensitivity to exenatide or any product components
* severe gastrointestinal disease, or pregnancy

Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No